Testicular cancer trial aims to slash relapse risk with stronger chemo
NCT ID NCT02341989
First seen Jan 05, 2026 · Last updated May 24, 2026 · Updated 21 times
Summary
This study compares two chemotherapy approaches for men with stage I seminoma testicular cancer who have a higher risk of the cancer coming back. One group gets a single round of the standard drug carboplatin, while the other gets a stronger combination of three drugs (BEP). The goal is to see if the stronger treatment lowers the chance of relapse more effectively. About 348 men aged 18-59 with tumors larger than 4 cm or invasion of the rete testis are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEMINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institutt for kreftforskning og molekylær medisin, St Olavs Hospital
Trondheim, Norway
-
St. Olavs University hospital HF
Trondheim, Norway
Conditions
Explore the condition pages connected to this study.